Abstract:Objective To construct DNA vaccine expressing influenza A ( H1N1) virus hemagglutinin (HA) antigen, and to evaluate its immunogenicity in mice. Methods The condon-optimized influenza A ( H1N1) virus HA sequence was synthesized and transferred to DNA vaccine vector, and its expression efficacy was proved by Western blotting in vitro. BALB/c mice were divided into DNA vaccine group and control group by simple random sampling for the evaluation of DNA vaccine immunogenicity. After the final inoculation, spleens and sera were collected from the immunized mice. HA-specific antibody responses in sera and T cell responses in splenocytes were quantified by ELISA and enzyme-linked immunospot assay ( ELISPOT) , respectively. In addition, hemagglutination inhibition (HI) and neutralizing antibodies were determined by HI assay and pseudovirus based neutralization assay, respectively. The t test was adopted in the comparison between the two groups. Results The constructed DNA vaccine could efficiently express HA protein in vitro. The inoculation of DNA vaccine in mice was capable of inducing vigorous T cell responses [429. 0 ± 113. 4 spot-forming cell (SFC)/106 splenocytes], the binding antibody liters in sera reached 16127.0 ±2698.0, and HI antibody tilers were 100. 8 ± 16. 9. All these data were significantly higher than those in vector control group (t=3.863, P=0.0042; t=5.734, P=0.0002; t =6. 018, P=0.0001, respectively). Furthermore,DNA vaccine could elicit high levels of neutralizing antibodies against homogenous H1N1 virus.but not against H1N1 heterogenous ones.Conclusions The constructed DNA vaccine is highly immunogenic and could induce high level of protective immunity.

[Evaluation on Construction and Expression in Vitro of Nucleic Acid Vaccine of Nucleoprotein of Influenza Virus A].

Construction and Expression of the Eukaryotic Expression Vector for Nucleoprotein Gene of Influenza Virus A

Construction of eukaryotic expressing plasmids for NP of influenza A virus and their transient expression in Hela cells

Construction and Immunogenic Evaluation of DNA Vaccine Expressing Influenza A (H1N1) Virus Hemagglutinin Antigen

[Evaluation of Influenza A Virus Nucleoprotein Based on Baculovirus Surface-Display Technology].

Construction of Eukaryotic Expressing Plasmids Encoding HA and HA 1 of Influenza A Virus and Their Transient Expression in HEK293 Cells

Construction and Primary Expression of Eukaryotic Expressing Vectors of Codon-Optimized H1N1 Influenza Virus HA and HA1 Gene

Construction of eukaryotic expression plasmid for receptor binding of influenza virus and their expression

[Clone Expression and Purification of Influenza A Virus Nucleoprotein Gene].

Immune Effects Against Influenza A Virus and a Novel DNA Vaccine with Co-Expression of Haemagglutinin- and Neuraminidase-Encoding Genes.

Prokaryotic Expression of NP Protein of Influenza A Virus H5N1 and Preparation of Polyclonal Antibody

Construction and Immunogenicity of Nucleic Acid Vaccine Expressing F Gene of Paramyxovirus ZH-1 Strain from Spotted Chicken

[Expression and Assay in Vitro of Phage Single Chain Antibody Against Nucleoprotein of Influenza Virus A Type].

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Construction of Replication-defective Recombinant Adenoviruses Expressing Influenza Virus Hemagglutinin and Study on Its Immune Responses

Construction and Sequence Analysis of the Eukaryotic Expression Vector for M2 Gene from Influenza A Virus

[Construction of Prokaryotic Expression Vector for Ag85A-HA2 Fusion Gene and Studies on the Immunity Efficacy of Fusion Protein Against Influenza A Virus].

Analysis of Avian Influenza Virus Epitopes and the Design of H5N1 Virus Genetic Engineering Vaccine

[Expression of influenza B virus hemagglutinin and its immunogenicity determination]

Construction and Immunogenicity Evaluation of Recombinant Bacillus subtilis Expressing HA1 Protein of H9N2 Avian Influenza Virus

Construction and immune efficacy of eukaryotic expression vectors of PPV VP2 gene with different antigen epitopes of PCV2 ORF2 gene